5 results
The primary objective of this study is to compare the efficacy of pitavastatin 1 mg once daily (QD), 2 mg QD, and 4 mg QD (after up-titration) to placebo in terms of the percentage reduction in LDL-C in children or adolescent patients with high-risk…
The primary objective of this study is to assess the safety of pitavastatin 1 mg QD, 2 mg QD, and 4 mg QD in children or adolescent patients with high-risk hyperlipidaemia over a period of 52 weeks.The secondary objective of this study is to assess…
To assess long-term safety and tolerability of pitavastatin 4 mg once daily (QD)To assess the efficacy of pitavastatin (4 mg QD) and simvastatin (40 mg and 80 mg QD) in terms of LDL-C target attainment (European Atherosclerosis Society [EAS] and…
1.) First, we hypothesize that a reduction of myocardial damage explained by lower levels of myocardial damage markers (e.g. troponin I, CK-MB) by sevoflurane may be related to a reduction of inflammatory mediators (i.e. TNF-α, CD11b/CD18 cells, and…
The primary objective of this study is to describe and to quantify the change in cardiac mechanoenergetics, expressed by PVL monitoring (reflected by the parameters stroke work, potential energy and pressure-volume area), in patients undergoing…